SINTX Chief Scientific Officer Retires and Director of R&D Steps Into Leadership Role
SALT LAKE CITY, Dec. 31, 2021 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT) (“SINTX” or the “Company”), an original equipment manufacturer of advanced ceramics, announced today its Chief Scientific Officer, Dr. Bryan J. McEntire, will be retiring at the end of 2021 after 17 years with the company. Dr. Ryan Bock will move into the role of Vice President of Research and Development (R&D) to take on the leadership of SINTX’s R&D activities. Following retirement, Dr. McEntire will continue supporting SINTX Technologies in the role of Emeritus Scientific Officer.
Dr. McEntire has worked in the advanced ceramic industry for 46 years and has co-authored more than 130 technical papers and presentations on ceramic materials, processing, and characterization. During his time at SINTX, he has been responsible for research and development, product development, testing and validation, manufacturing, and quality control for orthopedic implants produced from silicon nitride. Before joining SINTX, McEntire held various senior positions in notable ceramics and materials companies including Applied Materials, Saint-Gobain Industrial Ceramics Corporation, Norton/TRW Ceramics, and Ceramatec. He was elected as a Fellow of the American Society in 2012 and served as an invited short-course lecturer on Forming of Ceramics at the Annual Meeting of the American Ceramic Society from 1986 to 1995.
“Dr. McEntire has been a tremendous asset and friend to SINTX for nearly two decades,” said Dr. Sonny Bal, President, and CEO, SINTX Technologies. “While we’re sad to see him go, we are excited that he’ll maintain involvement through an advisory role.”
“It’s been both a privilege and a pleasure to work with and for the great men and women of SINTX in the development of advanced ceramic solutions for biomedical, industrial, aerospace, and armor markets,” said Dr. Bryan J. McEntire. “I couldn’t have ended my career with a more admirable organization, having strong management leadership, and outstanding technical and manufacturing talent. I wish them all the best in their future endeavors, and I hope to be of service to them in my new advisory role.”
Currently Director of R&D, Dr. Bock will continue biomaterial development efforts in addition to expanding application-focused research into antipathogenic and technical ceramic products as he steps into the role of Vice President of R&D when Dr. McEntire retires. Dr. Bock has supported SINTX through a variety of roles for 13 years and has an extensive background in advanced ceramics, colloid & surface science, and biomaterials.
“I am looking forward to leading SINTX’s R&D efforts which include rich collaborations with academic and industrial research groups around the world along with focused, application-driven research performed by our skilled and dedicated internal team,” said Dr. Ryan Bock, Director of R&D, SINTX Technologies. “It has been my great honor to have Dr. McEntire as a mentor and colleague during many years of biomaterial development activities, including the discovery of novel silicon nitride properties that enable SINTX to provide differentiated products into an ever-expanding variety of market spaces. His expertise and advice will be highly valued as we continue to find new applications for advanced ceramic materials.”
About SINTX Technologies, Inc.
SINTX Technologies is an OEM ceramics company that develops and commercializes advanced ceramics for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of ceramics for external partners. The Company presently manufactures silicon nitride powders and components in its FDA registered, ISO 13485:2016 certified, and ASD9100D certified manufacturing facility.
For more information on SINTX Technologies or its silicon nitride material platform, please visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: our products may not prove to be as effective as other products currently being commercialized or to be commercialized in the future by competitors; risks inherent in manufacturing and scaling up to commercial quantities while maintaining quality controls; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 22, 2021, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.
Business Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
Media Inquiries for SINTX:
Amanda Barry
Director of PR and Content
The Summit Group
abarry@summitslc.com
Released December 31, 2021